<h4>Introduction</h4>Epidermal growth factor receptor (EGFR) inhibitors, including tyrosine kinase inhibitors (TKIs), are associated with paronychia and pyogenic granuloma-like lesions (PGLs) that significantly impair patients' quality of life. This evidence concerns the gene EGFR and paronychia.